The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Is The Market Size Of The Apixaban Market Expected To Change Between 2026 And 2030?
The apixaban market size has shown substantial growth in recent years. It is anticipated to expand further, progressing from $3.16 billion in 2025 to $3.43 billion in 2026, at a compound annual growth rate (CAGR) of 8.5%. The historical growth trajectory can be linked to factors such as the growing prevalence of atrial fibrillation, increased awareness of stroke prevention, availability of generic anticoagulants, expansion of hospital infrastructure, and advancements in diagnostic technologies.
The apixaban market is projected to experience substantial expansion over the coming years. Its valuation is anticipated to reach $4.61 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.7%. This projected increase during the forecast period is primarily due to factors such as an expanding elderly demographic, a heightened need for less invasive surgical procedures, the incorporation of digital health monitoring systems, advancements in oral anticoagulant formulations, and an increase in homecare provisions. Key developments expected during this timeframe involve a greater embrace of direct oral anticoagulants (DOACs), an escalating prevalence of cardiovascular conditions, the broadening of post-surgical thromboprophylaxis initiatives, the creation of patient-focused anticoagulation treatments, and an uptick in outpatient and homecare management of anticoagulants.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15979&type=smp
What Drivers Are Expected To Influence The Apixaban Market During The Forecast Period?
The increasing occurrence of cardiovascular disease is projected to fuel the expansion of the apixaban market moving forward. This group of conditions affects the heart and blood vessels, comprising issues such as coronary artery disease, stroke, and heart failure. The escalating prevalence of cardiovascular disease is attributed to factors like sedentary lifestyles, poor dietary habits, tobacco use, obesity, high blood pressure, diabetes, and aging populations. Apixaban plays a role in managing cardiovascular disease by mitigating the risk of blood clots, thereby preventing conditions such as stroke, deep vein thrombosis, and pulmonary embolism. For instance, data from the American Heart Association, a US-based nonprofit organization, indicated that in January 2024, deaths due to cardiovascular diseases reached 931,578, which was an increase of fewer than 3,000 fatalities compared to the 928,741 recorded in 2023. Thus, the growing prevalence of cardiovascular disease is a significant impetus for the growth of the apixaban market.
How Is The Apixaban Market Structured Across Different Segments?
The apixaban market covered in this report is segmented –
1) By Dosage Form: Capsule, Tablets
2) By Application: Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users
Which Trends Are Shaping The Future Of The Apixaban Market?
Prominent companies within the apixaban market are concentrating on advancing innovative solutions, such as generic anticoagulant medicines, to boost treatment affordability, expand patient access, and strengthen their competitive standing. Generic anticoagulant medicines are therapeutically equivalent formulations designed to prevent blood clot formation by inhibiting key factors in the coagulation cascade, thus reducing the risk of stroke and other severe cardiovascular events. For example, in February 2023, Zydus Lifesciences, an India-based pharmaceutical company, secured final approval from the U.S. Food and Drug Administration (FDA) for its generic apixaban tablets in 2.5 mg and 5 mg strengths, which are identical to those of the reference drug Eliquis. This approval facilitates broader availability of cost-effective anticoagulant therapy across the U.S. market, thereby supporting improved patient access to crucial treatments for conditions including atrial fibrillation, deep vein thrombosis, and pulmonary embolism.
Which Major Players Dominate The Apixaban Market?
Major companies operating in the apixaban market are Bristol-Myers Squibb Company, Pfizer Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Hetero Drugs Ltd., Medichem S.A., Simson Pharma Limited, Aspen Pharmacare Holdings Limited, Daiichi Sankyo Company Limited, Fresenius Kabi AG, Centaur Pharmaceuticals Pvt. Ltd., Pinnacle Life Sciences Private Limited
Read the full apixaban market report here:
https://www.thebusinessresearchcompany.com/report/apixaban-global-market-report
Which Region Is Forecast To Lead The Apixaban Market In Terms Of Market Size?
North America was the largest region in the apixaban market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the apixaban market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Apixaban Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=15979&type=smp
Browse Through More Reports Similar to the Global Apixaban Market 2026, By The Business Research Company
Apixaban Market Report 2026
https://www.thebusinessresearchcompany.com/report/apixaban-global-market-report
Microbial Api Market Report 2026
https://www.thebusinessresearchcompany.com/report/microbial-api-global-market-report
Api Management Market Report 2026
https://www.thebusinessresearchcompany.com/report/api-management-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model